

Table 2: Neonatal outcomes in the pCMV group and the control group.

Outcomes	pCMV group(n=146)	Control group(n=17499)	Crude OR(95% CI)	aOR(95% CI)
BPD, n/N (%)	100/142(70.4)	6157/17036(36.1)	4.21(2.93, 6.04)	2.51(1.37, 4.60)
Moderate to severe BPD, n/N (%)	75/141(53.2)	2901/16654(17.4)	5.39(3.86, 7.52)	3.45(2.25, 5.29)
Severe ROP, n/N (%)	33/142 (23.2)	2094/16188(12.9)	2.04(1.38, 3.02)	1.25(0.76, 2.07)
PVL, n/N (%)	8/135 (5.9)	424/16059(2.6)	2.32(1.13, 4.78)	1.12(0.54, 2.32)
NEC \geq stage II after DOL 21, n/N (%)	8/146(5.5)	565/17499(3.2)	1.74(0.85, 3.56)	1.03(0.38, 2.78)
LOS after DOL 21, n/N (%)	13/146 (8.9)	585/17499 (3.3)	2.83(1.59, 5.02)	1.54(0.86, 2.76)
UTI after DOL 21, n/N (%)	12/146 (8.2)	178/17499 (1.0)	8.71(4.74, 16.00)	5.41(2.74, 10.70)
Failed hearing test, n/N (%)	39/129(30.2)	4120/15326(26.9)	1.18(0.81, 1.72)	0.98(0.64, 1.52)
Length of hospital stay, days, M (IQR)	83(67, 103)	48(36, 64)	52.5(52.1, 52.7)	17.3(23.3, 21.3)
Length of mechanical ventilation, M (IQR)	6(1, 17)	0(0, 5)	8.7(6.9, 10.6)	2.1(0.1, 4.1)

Abbreviations: OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; PVL, periventricular leukomalacia; UTI, urinary tract infection; DOL, day of life.

Generalized estimating equation model adjusted for relevant confounders, including gestational age, small for gestational age, male sex, cesarean birth, use of antenatal steroids, maternal hypertension, maternal diabetes, Transport Risk Index of Physiologic Stability score, use of pulmonary surfactant ≥ 2 times within 21 days, type of respiratory support on DOL 21, maternal breastfeeding within 21 days, red blood cell suspension infusion within 21 days, IVH \geq stage III, and patent ductus arteriosus

requiring treatment.

